This dynamic process helps regulate blood sugar levels, keeping them within a healthy range
Noninferiority to placebo was established, with a hazard ratio equal to 0.79 (95% CI: 0.57, 1.11) over the median observation time of 16-months
The effects of various dosing conditions e.g., fasting time and water volume, demographic covariates, and variability in exposure following single and multiple dose oral administration were investigated
While subcutaneous semaglutide, administered as a once-weekly injection, was the first format available for clinical use, recently, semaglutide has been developed into an oral formulation utilising innovative technology.48 The pharmacokinetic and pharmacodynamic distinctions between these formulations may lead to differences in the incidence of adverse events, including acute pancreatitis.49 Additionally, the inclusion of studies evaluating patients with or without diabetes is noteworthy, as the association between the use of the drug and the occurrence of acute pancreatitis could vary
